



## Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials

Harold E. Bays<sup>1</sup> · Robert S. Rosenson<sup>2</sup> · Marie T. Baccara-Dinet<sup>3</sup> · Michael J. Louie<sup>4</sup> · Desmond Thompson<sup>4</sup> · G. Kees Hovingh<sup>5</sup>

Published online: 27 April 2018

© Springer Science+Business Media, LLC, part of Springer Nature 2018

### Correction to: Cardiovasc Drugs Ther

<https://doi.org/10.1007/s10557-018-6784-z>

The original version of this article unfortunately contained a mistake in the Discussion section. The line that currently reads "During this 4-week period while off PCSK9 monoclonal antibody therapy, the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/or other lipid-altering drugs." should be changed to "During this 4-week stabilization period (while off PCSK9 monoclonal antibody therapy for at least 8 weeks), the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/or other lipid-altering drugs."

---

The online version of the original article can be found at <https://doi.org/10.1007/s10557-018-6784-z>

---

✉ Harold E. Bays  
hbaysmd@outlook.com

<sup>1</sup> Departments of Epidemiology & Medicine, Louisville Metabolic and Atherosclerosis Research Center (L-MARC), 3288 Illinois Avenue, Louisville, KY 40213, USA

<sup>2</sup> Cardiometabolics Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>3</sup> Clinical Development, R&D, Sanofi, Montpellier, France

<sup>4</sup> Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

<sup>5</sup> Department of Vascular Medicine - Internal Medicine Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands